同步放化疗联合度伐利尤单抗治疗肺癌的放射性肺炎剂量体积风险因素:日本多中心研究
该多中心研究纳入9个中心91例接受同步放化疗后度伐利尤单抗的非小细胞肺癌患者,评估放射性肺炎的频率、严重程度及正常肺剂量体积关系。结果显示肺炎发生率88%,≥2级34%,≥3级12%;多因素分析中V20和原发部位(上叶)为≥2级肺炎的选定因素,V20 cutoff为18.99%。结论强调联合度伐利尤单抗时V20的基本概念不变,但建议尽可能降低V20。
要点
- 91例患者中肺炎发生率88%,≥2级34%,≥3级12%。
- 多因素分析选定V20和原发部位(上叶)与≥2级肺炎相关。
- V20 cutoff值为18.99%,建议联合度伐利尤单抗时尽可能降低V20。
核心结论
- 联合度伐利尤单抗时同步放化疗强调V20的基本概念不变,但建议尽可能降低V20。
研究设计与样本
- 日本9个中心的多中心研究,纳入接受同步放化疗后度伐利尤单抗的非小细胞肺癌患者91例。
- 采用三维放疗、调强放疗和质子束治疗,评估肺炎频率、严重程度及正常肺剂量体积关系。
- 进行单因素和多因素分析识别风险因素,并估计Vx(X=5-40)的协变量调整风险比。
主要发现
- 从放疗开始到发生肺炎的中位时间为4.1个月。
- 肺炎见于80例(88%),其中≥2级31例(34%),≥3级11例(12%)。
- 80例肺炎中73例(91%)位于照射野内。
- 多因素分析中≥2级肺炎的选定因素为V20和原发部位(上叶)。
- V20 cutoff值为18.99%,V20<18.77与≥18.77之间存在显著差异。
关键数值与推荐
- V20 cutoff值为18.99%,V20<18.77与≥18.77之间差异显著。
- 多因素分析选定V20和原发部位(上叶)为≥2级肺炎的风险因素。
临床怎么用
- 联合度伐利尤单抗的同步放化疗中应尽可能降低V20。
- 关注原发部位为上叶的患者,其≥2级肺炎风险相关。
局限性
- 原文提及本研究存在一些局限性,但未具体说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate appropriate dose-volume parameters for avoidance of pneumonitis in use of chemoradiotherapy and durvalumab for treatment of lung cancer. MATERIALS AND METHODS: Patients with non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab at 9 centers were enrolled in the study. Three-dimensional radiotherapy, intensity modulated radiotherapy, and proton beam therapy were used. The frequency and severity of pneumonitis and the dose-volume relationship for normal lung were evaluated. Univariable and multivariable analyses were conducted to identify risk factors. A covariate adjusted hazard ratio was then estimated for the percentages of normal lung volume irradiated at ≥ X Gy (Vx) (X = 5-40) and lung volume non-irradiated at ≥ X Gy (X = 5-40), with the covariates selected in the variable selection. Cumulative incidence functions and covariate adjusted hazard ratios were also estimated for dichotomized variables, with estimated cut-off points. RESULTS: A total of 91 patients were enrolled in the study. The median time from the start of radiotherapy to development of pneumonitis was 4.1 months. Pneumonitis was observed in 80 patients (88%), including grade 2 or severe pneumonitis in 31 (34%) and ≥ grade 3 pneumonitis in 11 (12%). Pneumonitis was inside the irradiation field in 73 of the 80 patients (91%). The selected factors for ≥ grade 2 pneumonitis were V20, and primary site (upper lobe) in multivariable analysis. The cut off value of V20 was 18.99%, and there was a significant difference between V20 of < 18.77 and ≥ 18.77. CONCLUSION: Though there are some limitation of this study, the basic concept of concurrent chemoradiotherapy with an emphasis on V20 remains unchanged in use of durvalumab. However, we recommend reduction of V20 to as small a value as possible in use of this therapy.
引用
- Oshiro Y, Mizumoto M, Sekino Y, et al. Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan. Clin Transl Radiat Oncol. 2021. PMID: 34151033. doi:10.1016/j.ctro.2021.05.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。